Furthermore, we verified the pre‐clinical therapeutic potential of pharmacological IRE1α inhibition with MKC‐8866 on pre‐B ALL cells and consequently analysed the relevance of PI3K/mTOR signalling in pre‐B ALL cells. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.